Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12285666 | 0.91 | RXFP1 (0.73) | MAPTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL14707898 | 0.87 | MAPT (0.85) | MAPTMEN1KMT2ASMN1; SMN2THRB | |
| SCHEMBL14707904 | 0.86 | MAPT (0.60) | MAPTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL15854601 | 0.81 | POLB (0.74) | MAPTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL3309192 | 0.80 | S1PR2 (0.74) | MAPTKMT2ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL470775 | 0.79 | MAPT (0.85) | MAPTMEN1KMT2ATHRBTP53 | |
| SCHEMBL14707905 | 0.79 | RXFP1 (0.71) | MAPTMEN1KMT2ASMN1; SMN2THRB | |
| SCHEMBL12288667 | 0.77 | RXFP1 (0.70) | MAPTMEN1KMT2ASMN1; SMN2THRB | |
| SCHEMBL12285491 | 0.77 | RXFP1 (1.00) | MAPTSMN1; SMN2THRBTP53RXFP1 | |
| SCHEMBL12286344 | 0.76 | RXFP1 (0.84) | MAPTMEN1KMT2ATHRBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927561-B2 | Pyrimidinedione anti-viral compounds | Kineta, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130045229-A1 | Anti-Viral Compounds | Kineta, Inc. (US) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045229-A1 | Anti-Viral Compounds | MAVS, EIF2AK2, IRF3 | MAPT 3520/4885MEN1 4873/4885KMT2A 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.